Sino Biopharmaceutical (HKG:1177) said its colorectal cancer drug TQB2102 received the breakthrough therapeutic designation in China, according to a Hong Kong bourse filing Monday.
Shares of the company fell nearly 3% in midday trade Tuesday.
The designation will help expedite the drug's approval, the firm said.